Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium‑based contrast agent presented as a 0.5 mmol/mL injectable solution for intravenous use. It enhances magnetic resonance imaging of specific body regions and is employed in patients undergoing diagnostic MRI procedures to improve lesion detection and vascular delineation.

GNH USA supplies Multihance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Multihance (gadobenate dimeglumine) is a gadolinium‑based contrast agent used in magnetic resonance imaging to improve visualization of various anatomical regions.

- Brain and spine MRI: provides enhanced delineation of lesions, vascular structures and tissue contrast. - Abdominal and liver MRI: improves detection and characterization of focal liver lesions and vascular anatomy. - Cardiovascular MRI and MR angiography: enables high‑resolution imaging of cardiac chambers, coronary arteries and peripheral vessels.

Adverse reactions may occur following intravenous administration of Multihance.

Common Side Effects: - Nausea: mild to moderate feeling of stomach upset. - Headache: transient discomfort after injection. - Injection site discomfort: pain or burning at the infusion site. - Warmth sensation: brief feeling of heat during administration. - Dizziness: occasional light‑headedness. - Metallic taste: transient metallic sensation in the mouth.

Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis or angioedema requiring immediate medical attention. - Nephrogenic systemic fibrosis (NSF): rare fibrotic disorder in patients with severe renal impairment. - Hypotension: marked drop in blood pressure after injection. - Cardiac arrest: extremely rare but life‑threatening event. - Respiratory distress: severe breathing difficulty or bronchospasm. - Acute renal failure: sudden worsening of kidney function.

Use of Multihance requires careful assessment of patient risk factors and adherence to handling guidelines.

- Renal function assessment: evaluate glomerular filtration rate before administration, especially in patients with known kidney disease. - Pregnancy risk: category C; only use when the diagnostic benefit outweighs potential fetal risk. - Prior allergic reactions: avoid or pre‑medicate patients with a history of contrast‑agent hypersensitivity. - Severe renal impairment: contraindicated due to increased NSF risk. - Monitoring: observe patients for immediate adverse reactions during and after injection. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Multihance may interact with other agents that affect renal function or gadolinium handling.

Major Interactions (Avoid): - Renal replacement therapy (dialysis): may alter clearance and increase NSF risk. - Concurrent use of other linear gadolinium agents: raises cumulative gadolinium exposure. - Iron chelators (e.g., deferoxamine): can affect gadolinium binding and distribution.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask tachycardia associated with anaphylactoid reactions. - Hypotensive agents: additive blood‑pressure‑lowering effects. - Other contrast agents: cumulative impact on renal function and potential for overlapping adverse effects.